tbuckley/cabot-search huggingface dataset:
Abstract P191: Does ApoB/A1 Ratio Explain the Increased Risk of Cardiovascular Disease in Indian Asians Compared to Europeans?
Authors: Sian-Tsung Tan, Abtehale Al-Hussaini, Sunaina Yadav, Joban Sehmi, Mika Ala-Korpela, Paul Elliott, John C Chambers, Jaspal S Kooner
Journal: Circulation (2012)

Introduction Coronary heart disease (CHD) mortality is ∼2-fold higher in Indian Asians (IA) than in European Whites (EW). This is not accounted for by conventional CHD risk factors (type-2 diabetes, cigarette smoking, hypertension, obesity, total or HDL cholesterol). The INTERHEART Study has reported that ApoB/A1 ratio is the single strongest risk factor for CHD accounting for ∼50% of CHD risk; the contribution of ApoB/A1 ratio to the excess CHD risk in IA is not known. Hypothesis We tested the hypothesis that ApoB/A1 ratio is higher in IA than EW and accounts for the ∼2-fold excess CHD risk in IA, independent of conventional CHD risk factors. Methodology We studied 1361 IA and 1028 EW men and women aged 35-75 years, participating in the London Life Sciences Population Study. All participants completed a structured health questionnaire and had blood pressure, height, weight, waist-hip ratio, fasting biochemistry measured. Coronary artery calcium (CAC) was measured by electron beam CT; Agatston score &gt;0 was considered to indicate the presence of coronary atherosclerosis. Results Compared to EW, IA were younger, had higher prevalence of diabetes and hypertension, had higher WHR, and were less likely to smoke. Total and HDL cholesterol were lower, but Total-HDL cholesterol ratio was higher in IA ( table ). ApoB/A1 ratio was higher in IA compared to EW [0.71±0.15 vs. 0.67±0.16, p&lt;0.001], and was independent of conventional CHD risk factors (p&lt;0.001). In univariate analysis, ApoB/A1 ratio was associated with CAC in both populations [Odds ratio (OR) for CAC per 1 SD increase in ApoB/A1 ratio: IA 1.17 (1.05-1.30), p=0.006; EW 1.40 (1.23-1.59), p&lt;0.001]. After adjustment for age, gender, and total-HDL cholesterol ratio, there was no association between ApoB/A1 ratio and CAC [OR: IA 0.95 (0.74-1.21), p=0.66; EW 0.98 (0.72-1.33), p=0.88]. Conclusions ApoB/A1 is higher in IA compared to EW, but not independently associated with coronary calcification in either population. ApoB/A1 ratio does not explain the ∼2-fold increased risk of CHD in IA. Europeans Indian Asians P-value N 1028 1361 Age (years) 55.5 54.2 0.002 Male gender (%) 70.3 62.0 &lt;0.0001 Ever Smoked (%) 54.8 15.1 &lt;0.0001 ApoB/A1 ratio 0.67 (0.16) 0.71 (0.15) &lt;0.0001 Total: HDL Cholesterol Ratio 4.12 (1.10) 4.23 (1.03) &lt;0.0001 HDL cholesterol (mmol/L) 1.37 (0.39) 1.24 (0.32) &lt;0.0001 Type-2 Diabetes (%) 8.2 20.1 &lt;0.0001 Treated Hypertension (%) 19.2 31.3 &lt;0.0001 Waist-Hip Ratio 0.92 (0.08) 0.94 (0.08) &lt;0.0001 Coronary artery calcium score greater than 0 (%) 54.1 51.1 0.15 Table: Characteristics of study participants
Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients
Authors: M A Jenike, L Baer, P Summergrad, J B Weilburg, A Holland, R Seymour
Journal: American Journal of Psychiatry (1989)

Clomipramine was significantly superior to placebo in a 10-week double-blind, placebo-controlled trial in 27 outpatients who met DSM-III-R criteria for obsessive-compulsive disorder.
Prognostic impact of the <i>NFKB1</i> insertion/deletion promoter polymorphism on survival in patients with surgically resected gastric cancer
Authors: S. Kim, J. Kim, Y. Chae, S. Sohn, J. Moon, B. Kang, H. Chung, W. Yu, J. Baek
Journal: Journal of Clinical Oncology (2009)

e15638 Background: The present study analyzed the functional insertion/deletion polymorphism in the promoter region of NKFB1 gene and their impact on the prognosis for patients with gastric adenocarcinoma. Methods: Five hundred and three consecutive patients with surgically resected gastric adenocarcinoma were enrolled in the present study. The genomic DNA was extracted from paraffin-embedded tissue and the -94 insertion/deletion ATTG polymorphism of NFKB1 determined using a PCR- RFLP assay. Results: The NFKB1 promoter gene polymorphism was successfully amplified in 97.8% of the cases. There were no sexual differences in relation to the genotype and allele. No correlation was observed between the frequency of the genotype or allele and the T, N, or M stage. The multivariate survival analysis showed no association between the NFKB1 -94 insertion/deletion promoter polymorphism and the disease-free survival or overall survival of the patients with gastric cancer. Conclusions: The functional NFKB1 promoter polymorphism was not found to be a prognostic marker for Korean patients with surgically resected gastric adenocarcinoma. No significant financial relationships to disclose.
One-day surgery in breast cancer: Monoinstitutional results (experience during 2. 5 years)
Authors: F. Giovanardi, L. Scaltriti, F. Gibertoni, K. Cagossi, L. Cavanna, F. Artioli, G. Giovanardi
Journal: Journal of Clinical Oncology (2009)

e11596 Background: We want determine the effect of early discharge from hospital after surgery for breast cancer on physical and psychological illness. Moreover the study aimed to evaluate the management of post operative symptoms and post operative care. Methods: From January 2006 to July 2008, all breast cancer patients undergoing conservative breast cancer surgery or total mastectomy were offered surgery as an outpatient at One- Day Surgery Unit. Results: Three hundred seventy five patients underwent outpatient surgery for a total of four hundred four surgical procedures. The age of 375 patients varied from 14 years old to 94 years old, mean age was 55; in 79 of 404 (19.5%) surgical procedures patient remained in the hospital, for one night, after a surgical procedure regarding total axillary resection. Patients characteristics and post-operative complications were recorded for all 375 patients and 404 surgical procedures. All complications were treated by medical or nursing care. Complications included axillary seroma in nine patients (2.2 %), abscess in three patients (0.9%), pain in two patient (0.5%), hematoma formation in five patients (1.2%) for a total of 17 complications (4.2%). In our series, no hospital readmission was recorded during the first night and the first week and no death occurred. Conclusions: One day surgery for breast cancer patients is a totally safe and feasible procedure. We haven’t an increased rates of physical or psychological illness from early discharge after surgery for breast cancer. This policy can be recommended for patients with support at home. No significant financial relationships to disclose.
The correlation between the eradication of minimal residual disease (MRD) following alemtuzumab for CLL and overall survival
Authors: P. Moreton, B. Kennedy, A. Rawstron, P. Hillmen
Journal: Journal of Clinical Oncology (2004)

6566 Background: Alemtuzumab can produce remissions with very low or even undetectable levels of CLL. MRD flow cytometry for CLL can detect as few as one malignant cell in 100,000 blood or bone marrow cells. Methods: 91 patients with previously treated or refractory CLL received alemtuzumab between 1996 and 2003. All patients had regular bone marrow assessments by MRD flow cytometry during therapy with the aim of achieving the best possible response including to MRD negativity. Results: There were 74 men and 17 women with a median age of 58 (range 32 to 75). Patients received a median of 12 weeks of intravenous alemtuzumab therapy. There were 19 mild (grade 1 or 2) and 33 severe (grade 3 or 4) infectious episodes. Responses according to NCI criteria were: 33 (36%) patients achieved a complete response (CR), 17 (19%) a partial response (PR), and 41 (45%) no response. CLL was eradicated from the marrow below the level of detection by MRD Flow in 18 (20%) patients. There was no significant difference in response or survival between purine analogue refractory and purine analogue sensitive patients. Median survival was significantly longer in MRD negative patients compared to MRD positive CR, a PR, or no response (median not reached for MRD negative CR, 41 months for MRD positive CR, 30 months for PR and 15 months for NR, p=0.0004). Those patients that achieved an MRD negative CR had a significantly longer treatment free survival than patients with MRD positive CR, PR or non-responders (not reached for MRD negative CRs, 20 months for MRD positive CRs, 13 months for PRs, 6 months for NR, p<0.0001). The overall survival for the 18 patients with MRD negative remissions was 84% at 60 months. Eight (47%) of the MRD negative patients have converted to an MRD positive status at a median time of 28 months. Conclusions: MRD negative remissions are an achievable goal with alemtuzumab. Attaining this response leads to an improved overall and treatment free survival. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ILEX Oncology Ltd. ILEX Oncology Ltd. ILEX Oncology Ltd.
Dynamic changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States.
Authors: P. Cen, F. Banki, L. Cheng, L. R. Kaiser, K. Khalil, X. L. Du, R. J. Amato
Journal: Journal of Clinical Oncology (2010)

4130 Background: Previous data from the Surveillance, Epidemiology, and End Results (SEERs) Registry has demonstrated a 4-fold increase in the incidence of esophageal adenocarcinoma (EAC) in the United States over the past 3 decades. Our aim was to evaluate the changes in age, stage distribution, and overall survival (OS) of patients with EAC over time. Methods: Patients in the SEER database age ≥20 with invasive EAC (tumor invasion of basement membrane), diagnosed between 1973 and 2003 were reviewed. Variables included period of diagnosis, age, and tumor stage. Three-year overall survival (3y-OS) for patients with localized and regional stage, and 1-year OS (1y-OS) for patients with distant metastasis were analyzed using Kaplan-Meier probability. Results: 11,620 patients with invasive EAC were identified with 1,640 (14%) females and 9,980 (86%) males. There was no change in sex distribution over time. There were 5,040 (43%) patients age <65 and 6,580 (57%) age ≥65. The stage distribution was 22%, 35%, and 43% for localized, regional, and distant metastasis for patients < age 65, and 33%, 33%, and 34% for patients ≥ 65 respectively. The stage distribution and OS are shown in the Table. Stratified by stage, patients age <65 had better OS compared to patients ≥ 65 (p<0.0001), but there was significant improvement in survival of both groups throughout the study periods (p<0.0001). Conclusions: In the United States there has been a substantial improvement in OS of patients with invasive EAC over the last 3 decades. This improvement likely is related to improvement in treatment rather than detection alone, and applies to both younger and older populations. Younger patients were diagnosed at a more advanced stage, but have better survival compared to older patients. More advances in detection and treatment are required to further improve OS of patients with invasive EAC. 1973-1991 1992-1999 2000-2003 p value Overall survival (OS) % Localized (3 y OS) 29 38 42 <0.0001 Regional (3y OS) 13 18 25 <0.0001 Distant metastasis (1y OS) 16 16 23 <0.0001 Stage distribution Localized 579 (25%) 1,171 (30%) 1,575 (29%) Regional 777 (33%) 1,337 (35%) 1,829 (34%) Distant metastasis 980 (42%) 1,331 (35%) 2,041 (37%) No significant financial relationships to disclose.
Analysis of paired glioma tissues from initial diagnosis and recurrence in patients enrolled on NCCTG clinical trials: De-differentiation and association with survival
Authors: K. A. Jaeckle, P. A. Decker, K. V. Ballman, P. J. Flynn, C. Giannini, B. W. Scheithauer, R. B. Jenkins, J. C. Buckner
Journal: Journal of Clinical Oncology (2006)

1521 Background: Gliomas are known to progress from low to high grade at relapse, but the frequency is not well understood. It is unclear whether survival of these pts differ as a function of histologic subtype, and as measured from initial diagnosis and from relapse; yet such pts are frequently combined in clinical trials. Methods: Central review of paired glioma tissues obtained at initial diagnosis (DX) and recurrence was performed in 208 pts enrolled in prospective NCCTG trials (recurrence ≤ 90 d excluded). Kaplan-Meier, log rank, ANOVA, and chi-square tests were utilized. Results: Relapse from low (1–2) to high grade (3–4) occurred in 18/42 (43%) oligodendrogliomas (oligo), 28/41 (68%) oligoastrocytomas (OA), and 14/20 (70%) astrocytomas (astro); p=0.031. There were differences in median OS (in yrs; 95% CI) from initial DX: oligo-7.5 (5.0, 12.6); OA-4.5 (3.8, 5.6); and astro-3.3(1.8, 5.1), p=0.002; and OS from high grade recurrence: oligo-2.1 (0.9,3.0); OA-1.0 (0.8,1.3); and astro-0.7 (1.8, 5.1); p=0.02. Median OS from initial DX (yrs, 95% CI) also differed between primary (initial DX) GBM-1.7 (1.5–2.2); secondary (at recurrence) GBM-3.7 (2.8, 4.2) and non-GBM (initial+recurrence)- 5.5, (4.9–7.0) respectively, p &lt; 0.001. Mean time to recurrence (TTR), (yrs ± S.D.) also differed: 1.1±1.1; 2.9±1.8; and 4.0±2.9, respectively, p &lt; 0.001; as did median OS from recurrence (yrs, 95% CI) [0.7 (0.5, 1.1); 0.6, (0.5, 1.0); and 1.6 (1.1, 2.1), respectively], p &lt;0.001. OS differed between primary vs. secondary GBM from time of initial DX (p=0.041) and also from recurrence (p=0.017). Conclusions: Low grade astro and OA progressed to grade 3–4 more frequently than did pure oligo; these groups had significant differences in OS from initial diagnosis and from recurrence. There were significant differences in OS between pts with primary and secondary GBM from initial diagnosis and recurrence. These data have important implications in design of clinical trials. [Table: see text] No significant financial relationships to disclose.
MRI assessment of diastolic and systolic intraventricular pressure gradients in heart failure
Authors: Francisco Javier Londono Hoyos, Patrick Segers, Prithvi Shiva-Kumar, Prasad Konda, Payman Zamani, Rushik Bhuva, Anjaneyulu Dunde, Victor Ferrari, Julio Chirinos
Journal: Circulation (2014)

Background: Non-invasive assessment of left ventricular (LV) diastolic function is an important goal to better understand physiologic abnormalities in heart failure. The spatiotemporal pattern of LV blood flow velocities during early filling can be used to estimate intraventricular pressure gradients driving early filling. MRI can provide accurate flow velocity information in the LV, but this method has not been exploited to assess diastolic function in heart failure (HF). Aim: To assess differences in intraventricular pressure gradients in heart failure and preserved ejection fraction (HFPEF) and heart failure with reduced ejection fraction (HFREF), compared to subjects without HF. Methods: We studied 23 subjects without HF, 13 subjects with HFREF and 14 subjects with HFPEF. Intraventricular flow during diastole was measured using 2D in-plane phase-contrast MRI. We solved the Eulier equations to compute intraventricular pressure gradients during LV early filling (figure) and during ejection. Results: Whereas the initial velocity of wave propagation (was not significantly different between the groups, the terminal diastolic propagation velocity during early diastolic filling was significantly slower (P=0.004) in HFREF (5.2 m/s; 95%CI=3.9-6.8) than in patients with HFPEF (9.5; 95%CI=6.6-13.6) or subjects without HF (8.9; 95%CI=7.3-10.7). In contrast, HFPEF was associated with a greater amplitude of the reversal of the base-to-apex intraventricular pressure gradient during early filling (β=-0.34; P=0.04), which was driven by the inertial component. Conclusions: HFPEF and HFREF are associated with distinct patterns of intraventricular pressure gradient abnormalities during early diastolic filling. Our findings support fundamental differences in the nature of diastolic dysfunction in these 2 conditions.
Survival outcomes of renal pelvis and ureter cancer in a community-based cancer registry.
Authors: A. Akl, S. Santhanam Ethiraj, J. R. Fahrner
Journal: Journal of Clinical Oncology (2010)

e15141 Background: Studies on renal pelvis and ureter cancer are very small and are limited to tertiary care based cancer registry but community cancer registry studies are lacking. Hence we attempted to describe the epidemiological trends and survival outcomes of patients with renal pelvis and ureter cancer enrolled in a community hospital. Methods: All patients diagnosed with renal pelvis and ureter cancer are enrolled in our cancer registry were retrieved and reviewed for demographic and pathologic details, cancer recurrence, and vital status at last follow up. Results: Over a period of 18 years (1987 - 2004), there were 17 patients enrolled in the registry, with a diagnosis of renal pelvis and ureter cancer. There were 9 males and 8 females. Mean age at diagnosis was 62.5 (SD 13.0) years for males and 76.7 (SD 11.3) years for females. Transitional cell cancers were the most common: 9 /17 (53%) followed by papillary 5/17(29%) and renal cell cancer 2/17(12%). Overall Survival (O.S) for combined renal pelvis and ureter cancer was 76.5% at the 1yr, 58.8% at 3Yrs, 47% at 5yrs and 17% at 10yrs. The median overall survival and disease free survival was 4.8 yrs and 4.4 yrs respectively. Median survival of cancer involving renal pelvis vs. ureter was 5.7 vs. 4.4 yrs respectively (p=0.35).Six patients (35%) developed recurrent disease during follow up, after a median of 2.3 years (range: 0.25- 6.8 years) of which two (12%) had local recurrence only and four (23%) had distant recurrence with liver Involvement. Recurrence free median survival was 6.3 years .Treatment mainly included surgery like nephrectomy (41%), nephroureterectomy(35%) with median survival in these treatment groups were 8.9 yrs vs 6.5 yrs (p=0.42). Conclusions: Our results are concordant with several reported epidemiological and outcome studies from tertiary centers. Our study results supports that transitional cell carcinoma is the commonest ureteral cancer. Nephrectomy/nephroureterectomy achieved durable local control and disease free survival. No statistical difference was observed in the survival outcome of renal pelvis cancer compared to ureter cancer. No significant financial relationships to disclose.
Chemotherapy following surgery for stages IE and IIE non-Hodgkin's lymphoma of the gastrointestinal tract.
Authors: F A Shepherd, W K Evans, G Kutas, J C Yau, P Dang, J G Scott, H A Farquharson, W H Francombe, D Bailey, M A Baker
Journal: Journal of Clinical Oncology (1988)

Twenty-six patients were treated with chemotherapy following surgery for gastrointestinal non-Hodgkin's lymphoma (GI-NHL). The median age was 50 years (range, 20 to 76). The primary site included stomach (16 patients), small bowel (seven), large bowel (two), and mesenteric nodes (one). Following surgery, nine patients had macroscopic and four patients had microscopic residual disease, and 13 were felt to have had complete surgical resection. Thirteen patients were stage I and 13 were stage II. Sixteen patients were treated with COPP (cyclophosphamide, vincristine, procarbazine, prednisone), nine with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and one with CVP (cyclophosphamide, vincristine, prednisone). At a median follow-up of 50 months (8+ to 178+ months) ten of 12 stage I patients and nine of 14 stage II patients remain alive. Of the nine patients with macroscopic residual disease, four died of disease 6.5 to 11.0 months after diagnosis, and five are alive 8+ to 178+ months from diagnosis. Fourteen of the remaining 17 patients who had complete surgical resection are alive without disease. Death in the other three patients was due to multiple abdominal abscesses at 12 months, adenocarcinoma of the colon at 57 months, and dementia and progressive neurologic dysfunction at 65 months. No patient who had complete resection has relapsed or developed systemic disease after chemotherapy. These results suggest that complete surgical resection is an important prognostic factor and that chemotherapy without irradiation in completely resected localized GI-NHL can prevent local and systemic relapse resulting in long-term disease-free survival.
369O Timing of palliative care referral and its impact on receiving aggressive end of life care in patients with metastatic non-small cell lung cancer (NSCLC) in Southwest Sydney
Authors: P.S. Kok, H. Chan, C. Chao, J. Descallar, V. Bray, A. Tognela, P.Y. Yip
Journal: Annals of Oncology (2015)
Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.
Authors: R. A. Burger, M. F. Brady, M. A. Bookman, J. L. Walker, H. D. Homesley, J. Fowler, B. J. Monk, B. E. Greer, M. Boente, S. X. Liang
Journal: Journal of Clinical Oncology (2010)

LBA1 Background: BEV, a humanized anti-VEGF monoclonal antibody, has demonstrated single-agent activity in patients with recurrent EOC, or PPC. The therapeutic impact of concurrent ± maintenance BEV with standard chemotherapy (CT) was evaluated in an international, double-blind, placebo-controlled phase III trial. Methods: Eligible patients had newly diagnosed, previously untreated EOC, PPC or FTC following abdominal surgery for staging and maximal effort at tumor debulking; stage III (macroscopic residual disease) or stage IV disease. The randomly allocated regimens were (1) CT (IV paclitaxel 175 mg/m 2 + carboplatin AUC 6 cycles 1-6) + placebo cycles (C)2-22 (R1) (2) CT + concurrent BEV (15 mg/kg) C2-6 + placebo C7-22 (R2) (3) CT + concurrent BEV C2-6 + maintenance BEV C7-22 (R3) Infusions were administered d1 of a 21d cycle. The primary endpoint is progression-free survival (PFS) (radiographic, CA125, clinical criteria or death); secondary endpoints include overall survival, safety, and QoL. Results: 1,873 patients, median age 60, were enrolled from 9/05 - 6/09. Stage III optimally debulked (34%), stage III sub-optimally debulked (40%), and stage IV (26%) patients were similarly distributed in each treatment group. Grade 3 - 4 hypertension was reported in 1.6% (R1), 5.4% (R2), and 10.0% (R3). Grade ≥ 3 GI perforation, hemorrhage or fistula occurred in 0.8% (R1), 2.6% (R2) and 2.3% (R3). Relative to R1, the hazard of first progression or death for R2 was 0.908 (95% CI: 0.795 – 1.04, p=0.16) and for R3 was 0.717 (95% CI: 0.625 – 0.824, p&lt;0.0001). Conclusions: This study demonstrates that front-line treatment of EOC, PPC, and FTC patients with CT plus concurrent and maintenance BEV prolongs PFS. This is the first anti-angiogenic agent to demonstrate benefit in this population. [Table: see text]